Medicilon Reviews 

From its inception in 2004, Shanghai Medicilon Inc. (STAR Market,stock code: 688202.SH) has been committed to providing comprehensive research and development (R&D) services.

Based on key links of drug R&D, medicilon focus on the demand for innovation and the development of the global pharmaceutical industry. With our experience in serving domestic and foreign biomedical industries, we have built an integrated technical platform covering key technologies in drug discovery, pharmaceutical research, and preclinical research, in a bid to provide comprehensive preclinical new drug R&D for the global biomedical industry.

1. Drug Discovery

Medicilon’s Discovery Chemistry and Biology divisions have established a strong track record assisting thousands of clients worldwide with the discovery and development of small molecules, biologics as well as cell- and gene-therapies. Combining the most cutting-edge instrumentation and high-performance, experienced scientists, Medicilon has the expertise, capabilities and capacity to support projects of any size.

2. Drug development & CMC Services

Medicilon's pharmaceutical research links clinical candidate compounds with commercialized medicine. By developing and improving APIs (Active Pharmaceutical Ingredients) and formulations, we provide our clients with a comprehensive process and quality control system that is both innovative and GMP-compliant.

3. Preclinical Research

Medicilon’s Preclinical Research Division services include toxicology, pharmacology and efficacy studies, absorption, distribution, metabolism, and excretion (ADME), drug metabolism and pharmacokinetics (DMPK), as well as bioanalytical solutions for small molecules, biologics, and medicinal herbs. We maintain a large in-house library of animal disease models to meet the research demands in different therapeutic areas. Medicilon can also assist clients in the preparation of a preclinical safety evaluation package.